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The parenteral administration of antivenoms is the cornerstone of snakebite envenoming therapy. Efforts
are made to ensure that antivenoms of adequate efﬁcacy and safety are available world-wide. We address
the main issues to be considered for the development and manufacture of improved antivenoms. Those
include: (a) A knowledge-based composition design of venommixtures used for immunization, based on
biochemical, immunological, toxicological, taxonomic, clinical and epidemiological data; (b) a careful
selection and adequate management of animals used for immunization; (c) well-designed immunization
protocols; (d) sound innovations in plasma fractionation protocols to improve recovery, tolerability and
stability of antivenoms; (e) the use of recombinant toxins as immunogens to generate antivenoms and
the synthesis of engineered antibodies to substitute for animal-derived antivenoms; (f) scientiﬁc studies
of the contribution of existing manufacturing steps to the inactivation or removal of viruses and other
zoonotic pathogens; (g) the introduction of novel quality control tests; (h) the development of in vitro
assays in substitution of in vivo tests to assess antivenom potency; and (i) scientiﬁcally-sound pre-clinical
and clinical assessments of antivenoms. These tasks demand cooperative efforts at all main stages of
antivenom development and production, and need concerted international partnerships between key
stakeholders.
 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved.1. Introduction
Envenomings due to snakebites are a major neglected tropical
disease affecting predominantly poor people living in rural settings
in Africa, Asia, Latin America and Oceania [1e3]. Although accurate
statistics are often unavailable, the yearlyworld-wide occurrence of
envenomingsmay range between 421,000 and 1,841,000, provoking
from 20,000 to 94,000 fatalities [4]. In addition, a signiﬁcant
proportion of these accidents endupwithpermanent tissuedamage
and sequelae, with high socioeconomic and psychological impacts
[1,3]. The parenteral administration of antivenoms of animal origin
is the cornerstone therapy of snakebite envenomings since the ﬁrst
serum antivenimeux was developed in the last decade of the 19th
century [5].
Antivenoms are currently manufactured by at least 45 labora-
tories in all continents (see http://apps.who.int/bloodproducts/
snakeantivenoms/database/). The basic antivenoms production
process involves the immunization of animals, usually horses but
sometimes other species, with venoms from a single or various
snake species. After collection of blood or plasma, the plasma isþ506 2292 0485.
rrez).
for Biologicals. Published by Elsevifractionated to extract and purify the active immunoglobulin
substances. Depending on the fractionation protocol, three types of
active antivenoms substance are obtained: (a) whole IgG, currently
isolated using either ammonium sulphate or caprylic acid [6,7]; (b)
F(ab’)2 fragments, prepared by pepsin digestion and ammonium
sulphate or caprylic acid fractionation [8,9]; and (c) monovalent
Fab, prepared by papain digestion and ammonium sulphate frac-
tionation [10]. After ﬁlling in the ﬁnal containers, antivenoms may
be kept liquid or be freeze-dried to increase their stability [11].
Some manufacturers have introduced process variations, such as
chromatography and pasteurization, to improve purity and/or viral
safety [9]. Large heterogeneity in technologies used, scale of
production, staff qualiﬁcation, quality control protocols, and extent
of implementation of good manufacturing practices (GMP) are
found among manufacturers. A major step forward as a guideline
for improving antivenoms quality world-wide is the recent WHO
publication entitled “Guidelines for the Production, Control and
Regulation of Snake Antivenom Immunoglobulins” [11], which
offers manufacturers and regulators with practical recommenda-
tions on selection and preparation of venoms, maintenance of
snakes, immunization protocols of horses, collection and storage of
blood/plasma, plasma fractionation methods, quality control tests,
viral safety measures, pre-clinical and clinical assessment of efﬁ-
cacy and safety, and general regulatory approaches. Theseer Ltd. All rights reserved.
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manufacture and quality control.
Although most current antivenoms exhibit improved efﬁcacy
and safety proﬁles compared to former generation products, issues
still need to be addressed for further improving antivenom design
and manufacture. These issues demand concerted efforts in
research and development, and the translation of research ﬁndings
into the technological realm for preparing higher quality anti-
venoms. The present work highlights some of the on-going tech-
nical development areas as well as issues to be addressed for
improving antivenom technology. Additional aspects, such as
production economics, purchase and distribution systems, acces-
sibility in developing countries, proper training of health workers
in the diagnosis and treatment of snakebite envenomings, and
correct use of antivenoms in the clinical setting, although highly
important, are beyond the scope of this work and, therefore, not
addressed here.
2. Towards a knowledge-based approach in the design of
immunization mixtures: taking advantage of research in
venom biochemistry, immunochemistry and toxicology
Unlike antigens used for the production of tetanus and diph-
theria antitoxins, and rabies immunoglobulins, the venoms of
snakes are characterized by an astonishing inter- and intraspecies
variability [12,13]. Consequently, the selection of venoms for
inclusion in immunizing mixtures is critical in antivenom produc-
tion [11,14]. Many decades ago, the selection of venoms for
immunization was often based on toxic proﬁle of venoms and
broad taxonomic considerations, without considering biochemical
and immunochemical analyses of venoms. Studies have shown
that, whereas for some venoms the designs were appropriate, for
others they were misleading, generating antivenoms ineffective
against the venoms of some medically-relevant snake species. In
the last decades, the knowledge of venom biochemistry, toxicology
and immunology has grown exponentially, providing important
information for the improvement of antivenoms. This gap between
basic knowledge of venom composition and effects and practical
antivenom production should be ﬁlled to enhance antivenoms
quality and efﬁcacy.
Current proteomics tools make detailed characterization of
venoms now possible (see [15e17] for reviews). In addition, toxi-
cological and enzymatic assays can be used to characterize venom
activities. Moreover, routine electrophoretic and chromatographic
analytical procedures allow the investigation of individual, onto-
genetic and regional variability in venom composition. This set of
analytical tools is currently used by many laboratories to charac-
terize venom composition and variability. One application is the
preparation of national or regional reference venoms for species
with wide distribution and signiﬁcant medical impact. Examples of
such wide distributed species are Bitis arietans in Africa [18], Daboia
russellii in Asia [19], Bothrops atrox [20] and B. alternatus [21] in
South America, Crotalus viridis in North America [22], and Vipera
aspis in Europe [23]. In these cases, a conspicuous pattern of
regional variation in venom composition requires careful analysis
to select the most adequate mixture of venoms of various
geographical origins to prepare representative reference venom
pools. Such pools are likely to elicit an immune response effective
in the neutralization of venoms from different regions and are also
useful for quality control of antivenoms.
Venoms of Central and South American Crotalus species illustrate
the usefulness of these analyses. The venom of adult specimens of
C. simus, distributed in Central America, is abundant in metal-
loproteinases and poor in the neurotoxic dimeric phospholipase A2
complex ‘crotoxin’ [24]. In contrast, the venomof neonate specimensof C. simus, and those of neonate and adult specimens of the South
American subspecies of C. durissus present low amounts of metal-
loproteinases and high concentration of crotoxin, therefore having
higher toxicity and provoking a different pathophysiology compared
toC. simusvenom[13,25e27].Moreover, someC.durissuspopulations
contain the toxin crotamine, which provokes contracture and spastic
paralysis, whereas other populations lack this protein [13,28,29].
Such proteomic information allows a knowledge-based design of the
composition of immunizing mixtures for the neutralization of Cro-
talus sp venoms in Central and South America. In this case, the
mixture should include venom(s) containing high amounts of cro-
toxin and crotamine, e.g. from some populations of South American
C. d. terriﬁcus, and venom(s) containing high amounts of metal-
loproteinases, e.g. from adult C. simus. Both types of venoms contain
thrombin-like serine proteinases, which are necessary to elicit the
formation of antibodies able to neutralize coagulopathy. Biochemical
analyses have therefore paved theway for scientiﬁcally-based design
of the most adequate mixture of venoms for immunization, making
possible the generation of antivenoms effective for the treatment of
rattlesnake envenomings in Central and South America.
When venom mixtures are designed on the basis of regional
variation analysis, such mixtures should be tested to demonstrate
that they evoke an antibody response able to neutralize key toxic
activities in medically-relevant venoms. Such testing should be
performed by combining neutralization assays, e.g. neutralization
of lethality and other activities, and by immunochemical analysis of
reactivity [16]. In recent years, proteomic analytical tools have been
adapted to assess the immune reactivity of antivenoms against
individual venom components [16,29]. This methodological
approach, named ‘antivenomics’, permits the classiﬁcation of
toxins in a venom as C-toxins (completely immunodepleted by an
antivenom), P-toxins (partially immunodepleted by an antivenom),
and N-toxins (not depleted by an antivenom) [17]. Antivenomics, in
combination with the study of neutralization of toxic and enzy-
matic activities of venoms by antivenoms [11,30], are highly useful
to test whether a mixture of venoms elicits an antibody response
capable of recognizing and neutralizing the most relevant compo-
nents in a venom (see, for example, [31e33]); it is necessary to
analyze whether the traditional immunizing mixtures used in the
production of many antivenoms are the most adequate or whether
they need to be revised based on biochemical and toxicological
data. Likewise, the design of new antivenoms should take advan-
tage of this arsenal of analytical resources.
Bioinformatic tools should be also incorporated in the analysis
of venom variability and in the selection of the most appropriate
venom mixtures for immunization. The proteomic and tran-
scriptomic information gathered on snake venoms allows for the
identiﬁcation of common antigens and potential toxin epitopes
[34,35]. This information, in turn, can be used to predict which
combinations of venoms elicit an effective immune response
against the most relevant toxins in a venom or in a group of
venoms. Evidently, applying proteomic, transcriptomic and bio-
informatic methods in the design of venommixtures for antivenom
production demands the collaboration between research and
antivenom development/manufacture groups. Such cooperative
scenario should be promoted by funding agencies, health authori-
ties and manufacturers alike (Fig. 1).
3. The selection of the most effective venom mixtures for
immunization: integrating epidemiological, clinical and
immunological information
The design of optimal venom mixtures for immunization should
also be based on epidemiological and clinical criteria. Renewed
research efforts of snakebite epidemiology and clinicalmanifestations
Fig. 1. Suggested development tasks (circles at right) in venom collection and preparation, design of venommixtures for immunization, and quality control of venoms (boxes at left)
to improve quality, safety and efﬁcacy of antivenoms.
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a venom needs to be included in a mixture for immunization, and
whether monospeciﬁc or polyspeciﬁc antivenoms are required [11].
For instance, for species that inﬂict accidents with clinical manifes-
tations that allow the identiﬁcation of the offending snake, a mono-
speciﬁc antivenom may be indicated. Such is the case of the crotalic
antivenoms produced in various South American laboratories against
the venom of C. durissus (see http://apps.who.int/bloodproducts/
snakeantivenoms/database/). In contrast, species of Bothrops in Latin
America induce a similar picture of pathological and pathophysio-
logicalmanifestations, thus requiringpolyspeciﬁc antivenoms [27,32].
Similarly, a new polyspeciﬁc antivenom for sub-Saharan Africa is
prepared by immunizing horses with amixture of the venoms of two
viperid species, Echis ocellatus and Bitis arietans, and one elapid
species, Naja nigricollis [36]. The rationale behind this design is that,
unlike other cobra species whose envenomings are characterized by
neurotoxic manifestations, those by N. nigricollis and related spitting
cobras areprimarilyassociatedwith local tissuedamage. Thedifﬁculty
indiscerningbetweenviperid and elapid bites in this case justiﬁed the
preparation of an antivenom that would neutralize both types of
venoms.
Novel epidemiological and clinical ﬁndings may reveal the
occurrence of envenomings by species hitherto unknown to repre-
sent a relevant health hazard, or presenting unusual clinical mani-
festations. Examples are Hypnale hypnale [37], Bungarus candidus
[38] and Bothrops lanceolatus [39]. Such information may justify
including these venoms in immunizing mixtures used for poly-
speciﬁc antivenom preparations or, if considered necessary, for the
development of new monospeciﬁc antivenoms. Likewise, when
preparing pools of immunizing venoms, evidence of geographical
variation in the clinical presentation of envenomings, such as by
Daboia russellii in various regions of Asia [19,40] should be consid-
ered, in conjunction with the biochemical and immunological
criteria discussed above. Therefore, a careful and knowledge-based
analysis, integrating biochemical, immunological, epidemiological
and clinical information, should be performed for designing
immunizing mixtures used in antivenom manufacture in different
regions of theworld. A selected immunizing venommixture shouldbe validated by preparing a pilot antivenom batch and by testing it
by neutralization assays against the targeted venoms.
4. Scientiﬁc names matter: the importance of keeping up
with taxonomic changes
Snake taxonomy and systematics are active research ﬁelds.
Changes in species and genera names are regularly proposed
following ever-growing morphological, molecular and bio-
informatics data (see, for example [41]). When such taxonomic
modiﬁcations occur in medically-relevant species, they carry rele-
vant implications for antivenom manufacture as well as for tox-
inological research and envenoming treatment protocols [11]. This
affects the identiﬁcation of snakes in collections and of venom
samples used in research and in antivenom manufacture and
quality control. This issue is particularly relevant when antivenom
production laboratories rely on external sources for venom supply,
thus depending on the capacity of such sources to correctly identify
the species, and the geographical origin of specimens from which
venoms are collected. The potential problem of species misidenti-
ﬁcation, due to using old scientiﬁc names, can be circumvented by
close interaction between groups working in snake taxonomy and
systematics and manufacturing laboratories, and by an appropriate
traceability of venom pools used in production. Regular publication
of reviews, by joined teams of taxonomists and clinicians,
summarizing the most relevant taxonomic changes involving
medically-relevant snake species, facilitates such ﬂow of informa-
tion [11,42]. Likewise, the involvement of herpetologists in venom
and antivenom-producing facilities ensures correct scientiﬁc
names in species identiﬁcation and in antivenom labels.
5. Improving the selection, management and immunization
protocols in animals used for antivenom production
5.1. Selection and clinical assessment
Antivenoms are produced by immunizing animals with whole
venoms or isolated venom components, and this approach is likely
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nization, bleeding and clinical control are performed following
a rather empirical and poorly-controlled process. The WHO anti-
venoms guidelines include a section dealing with animal selection
and care, emphasizing this critical aspect of antivenom production
[11]. Future efforts should focus in areas such as:
(a) The development and widespread distribution of immunodi-
agnostic and nucleic acid testing kits to detect relevant
microbial infections in animals used in immunization. The
collaboration between veterinary immunologists and anti-
venom producers should be promoted to facilitate the devel-
opment, validation and implementation of diagnostic kits
adapted to the economics and speciﬁcs of antivenom manu-
facture. This would contribute to the proper selection of
animals introduced in immunization programs.
(b) The establishment of validated protocols for the follow-up of
the health status of immunized animals, including veterinary
care, use of clinical laboratory methods and implementation of
computerized tools for traceability of health controls. Studies
on the clinical and laboratory alterations occurring in animals
immunized with different venom mixtures should be
promoted to strengthen knowledge-based maintenance
programs.5.2. Improving animal immunization for antivenom production
Animal immunization is a critical stage in antivenom produc-
tion. Essentially all quality factors, i.e. efﬁcacy, safety, availability
and cost, largely depend on the neutralizing activity reached by the
plasma of immunized animals. High neutralizing titers result in
beneﬁts such as: (a) higher volume of antivenom, (b) higher
potency, (c) lower total protein formulation, and, consequently, (d)
more affordable products [43]. Therefore, procedures to obtain
hyperimmune plasma need to be optimized. This should include
considerations to (a) animal species used, (b) preparation and
control of venoms used as immunogens, (c) immunization sched-
ules, and (d) validation of antibody response assays (Fig. 2).Fig. 2. Proposed development tasks (circles at right) in. animal selection and care, immuni
antivenoms.5.2.1. Animal species used as source of immunoglobulins
Horses, and in some cases sheep and donkeys, are currently used
to raise hyperimmune plasma for antivenom production [44e46].
Most experience is with horses, and they will likely remain
predominantly used in the future. However, other species that could
provide satisfactory high-yield antibody responses may be highly
convenient in some regions. For instance, camelids (such as camels
or llamas) can adapt better thanhorses inparts of Africa,Middle East
and highlands of South America [47,48]. Immunization of hens has
also beenproposed as a lowcost, high-yield procedure for preparing
avian antibodies [49e52]. Investigating the characteristics of the
immune response of these species to snake venoms is necessary
[53], as well as considering the possible risks of allergy to egg or
serum proteins. Even with horses, the basic immune response to
venoms has received little attention and demands future studies
aiming at understanding antigen presentation, kinetics of response,
immune regulation by venom components, development of anti-
body afﬁnity, genetic aspects of the immune response, etc. Clearly,
cooperation between antivenom producers, veterinarians and
immunologists should be fostered to clarify these issues.
Immunoglobulins from different species have different physi-
cochemical characteristics to be considered for antivenom
production. Horses respond to venom immunization by generating
predominantly w180 kDa [54] IgG(T) antibodies [55]. Camelids
produce two types of antivenom antibodies: (a) heterotetrameric
IgGs (w160 kDa), corresponding to the IgG1 subclass, composed by
two identical heavy chains and two identical light chains, and (b)
homodimeric IgG (w100 kDa), the heavy chain antibodies, corre-
sponding to the IgG2 and IgG3 subclasses, made of two identical
heavy chains without light chains [56]. The stability of these cam-
elid IgGs differ [53]. In turn, hens producew180 kDa IgYantibodies
composed by two heavy chains and two light chains [50]. These
various immunoglobulins should be compared for neutralizing
capacity against venom toxins, stability at different temperatures,
storage conditions, and tendency to induce adverse reactions
[53,57,58]. For instance, high degree of glycosylation of horse IgG(T)
was thought to induce adverse reactions [59,60], but this is not
supported by a recent clinical trial comparing equine and ovine-
derived whole IgG antivenoms [61].zation and bleeding programs (boxes at left) to improve quality, safety and efﬁcacy of
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processes used by production laboratories. Automated plasma-
pheresis should be considered in place of the traditional whole
blood collection protocols (“manual apheresis”) since it provides
a more controlled and aseptic alternative to obtain equine plasma
[62]. Likewise, the clinical effects of bleeding programs on immu-
nized animals should be investigated to develop protocols which
maximize plasma yield without harming animals.
5.2.2. Manipulating the antigen carefully: improvement of venom
preparation and use
Proper collection, handling, storage and preparation of venoms
for immunization are critical to ensure an adequate immune
response. This is particularly relevant considering that venoms are
often prepared by independent laboratories. Collection and storage
procedures of venoms should be validated to ensure absence of
physicochemical alterations of venom proteins that could poten-
tially affect the efﬁciency of the immunization [11,63]. Physico-
chemical characteristics of venom toxins can be affected by
inherent venom instability, e.g. due to proteases [64], and/or stress
produced during venom drying. Loss of important epitopes may
affect venom antigenicity, generating a poor immune response.
Therefore, processes used to obtain and stabilize venoms (i.e.
desiccation or freeze-drying) should be properly validated, and the
pharmacological and biochemical properties of venom batches
used as immunogens should be characterized. In this context,
protocols aimed at assessing venom quality are critical in anti-
venom-producing laboratories (see [11] for details).
Some studies have described different methods to detoxify
venoms for immunization [65e68], a process that may induce loss
of antigenicity. Some producers use detoxiﬁed venom for immu-
nization, especially when dealing with highly toxic venoms. This is
necessary in high-dose immunization schemes that lead to signif-
icant damage to animals when using native venoms. However,
since snake venoms are highly complex mixtures of many antigens,
the effect of such detoxifying steps on different toxins should be
carefully evaluated, a task that requires detailed biochemical
knowledge and analysis of the venoms. As discussed below, the
trend is to reduce the total amount of venom injected in animals,
taking advantage of novel immunization strategies. This approach
should be promoted to achieve good immune responses with
native venoms, thus avoiding the need for venom detoxiﬁcation.
Snake venom antigenicity may also be altered by other venoms
used as co-immunogens for producing polyspeciﬁc antivenoms.
Immunosuppressive activity has been demonstrated when using
Lachesis muta [69] and Crotalus durissus terriﬁcus [70,71] venoms.
This should be considered and investigated by laboratories
producing polyspeciﬁc antivenoms. A case by case analysis, where
different combinations of venoms are tested for occurrence of
negative immunomodulation, is recommended. Decisions could
then be drawn on whether a polyspeciﬁc antivenom should be
prepared by immunizing animals with a venoms mixture or by
mixing plasmas of animals immunized with the corresponding
single venoms [11]. Likewise, the immunological mechanisms
behind such immunomodulatory events should be investigated to
take measures regulating these negative interactions.
5.2.3. Adjuvants and immunization schemes
Adjuvants are used to improve the antibody response towards
immunogens [72]. The most frequently used are aluminum salts
and Freund’s adjuvants [11,36,73], Freund’s complete and incom-
plete adjuvants being the most effective. However, since they
induce tissue damage at the site of injection, their use is limited to
the animal priming and ﬁrst immunogen boosters [43]. It is
necessary to explore new, less toxic adjuvants. Examples includeliposomes [74] and stimulation of immune mechanisms associated
with cell activation and cytokine production [75]. Cross-talk
between vaccine developers and antivenom producers should be
encouraged to harness knowledge generated in the vaccine ﬁeld in
the development of new adjuvants for application in antivenom
manufacture.
Likewise, a critical assessment of current immunization schemes
should be performed. This is a key area in antivenom manufacture
that has received relatively little attention; in many cases, such
protocols were developed decades ago and have remained
unchanged. A number of old immunization schemes were based on
the administration of rather large doses of venom [76,77], with the
consequent effect on animal health and, possibly, on the generation
of immune tolerance associated with a poor antibody response.
Antivenomproducers and research anddevelopment groups should
design novel immunization schemes, analyzing variables such as
venom doses, number of immunizations, time interval between
venom injections, number of anatomical sites injected and volume
of injection per site, among others, as well as exploring novel adju-
vants at different stages of the immunization schedule. Recent
advances include the use of low doses of venom [78] and low dose,
lowvolume,multi-site protocols [79],withhighly promising results.
The future immunization protocols for antivenom production will
likely be based on low doses of native venoms, administered with
novel adjuvants, and injected at anatomical sites selected to maxi-
mize the contact between venom antigens and the immune tissues
and cells. Here again, cooperative research is urgently needed.
5.2.4. The assessment of antivenom antibody response
Development of new immunization protocols and routine
assessment of antivenom antibody response in immunized animals
demand laboratory determination of (a) the immune response to
facilitate the selection of the best responders, and (b) the optimal
time of bleeding. In many laboratories, such assessment is per-
formed by routine potency test usingmice. This requiresmanymice,
especially if the immunological response is tested at individual level.
If, on the other hand, pools of plasma are tested, the inter-individual
differences in theantibody responsearemasked,with thepossibility
of keepingpoor responderswithin thegroup.Hence, it is desirable to
develop in vitro tests to followup the individual immune responseof
animals to venoms. Such tests should correlate with the traditional
potency assay in mice to ensure that the selection of good
responders and bleeding times are based on effective neutralizing
antibody responses (see Section 9.2).
6. Plasma fractionation: towards antivenoms of high
physicochemical quality, satisfactory yield and low cost
Antivenoms are manufactured by fractionating the plasma of
immunized animals to generate products containing either whole
IgG or immunoglobulin fragments F(ab’)2 or Fab [11,44,46]. Anti-
venoms from different laboratories vary in physicochemical char-
acteristics, such as total protein concentration, level of protein
aggregates and non-IgG plasma proteins, and presence of Fc frag-
ment in whole IgGs. These may inﬂuence the risk of early and late
adverse reactions, the frequency of which greatly differ among
products, from 6% [80] to higher than 80% [81e83]. Late adverse
reactions likely correspond to type III hypersensitivity, mediated by
the formation of immune complexes between antivenom proteins
and human antibodies generated against antivenom. The incidence
of these reactions seems related to the total amount of foreign
protein administered [84]. Poor tolerability of some whole IgG
antivenoms was long been thought to be due to the presence of Fc.
However, IgG and F(ab’)2 antivenoms of good physicochemical
proﬁle were found to induce a similar low incidence of early
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physicochemical features, i.e. turbidity, high content of protein
aggregates or non-IgG contaminating proteins, exhibit low tolera-
bility [81e83,86e88]. The mechanisms responsible for early
adverse reactions, although likely dependent on physicochemical
characteristics [44,89], have not been completely elucidated
[44,46], a subject that requires renewed research efforts.
6.1. State of the art: basic technological platforms for the
puriﬁcation of antivenom active substances
6.1.1. Puriﬁcation of whole IgG
Salting-outwith ammoniumor sodium sulfate has long been the
main whole IgG puriﬁcation procedure. A typical protocol involves
two precipitation steps at two different salt concentrations, in
addition to ‘euglobulins’ removal by diluted acid precipitation [7].
However, when not properly standardized, this fractionation
protocol yields a product with high content of non-Ig proteins, such
as albumin and non-Ig globulins, as well as excessive protein
aggregates [6], with a detrimental impact on safety [88]. Whole IgG
antivenoms of good physicochemical proﬁle and purity are readily
obtained by caprylic acid (octanoic acid) precipitation of non-IgG
plasma proteins [6,90]. Caprylic acid fractionation involves slow
addition of caprylic acid to undiluted plasma. Precipitated protein is
separated from the solution by ﬁltration or centrifugation. Immu-
noglobulins are then diaﬁltered, formulated, sterilized by ﬁltration,
and dispensed in ﬁnal containers [6,11]. Caprylic acid fractionation
generates antivenoms of relatively high purity with little aggregate
content, in part because the IgG is not precipitated during process-
ing. The process yield isw60% [6]. The efﬁcacy and safety proﬁles of
such product have been demonstrated in clinical trials [61,82,88,91].
6.1.2. Puriﬁcation of F(ab’)2 fragments
Most manufacturers use optimized versions of the F(ab’)2 anti-
venom production protocol published by Pope in 1939 [8,92]. This
technique involves the digestion of plasma proteins by pepsin,
usually at 1 g/L and pH 3.3 for 1 h at 30e37 C [11], although
different protocols yield similar results. After pH adjustment with
NaOH, a solution of ammonium sulphate is added under stirring to
reach 12% (w:v) ﬁnal concentration. The precipitate is eliminated
by either ﬁltration or centrifugation, and the solution is submitted
to 56 C heating for 1 h (‘thermocoagulation’). The mixture is
ﬁltered or centrifuged to eliminate the precipitate. The pH is
adjusted to neutral value with NaOH, and a solution of ammonium
sulphate is added under stirring to reach 23% (w:v) concentration,
to precipitate F(ab)2 fragments [11]. After an additional ﬁltration, or
following centrifugation, the F(ab’)2 precipitate is dissolved, dia-
ﬁltered, formulated, sterile-ﬁltered, and dispensed [11,46]. Caprylic
acid precipitation of non-F(ab’)2 proteins can be introduced in
substitution of ammonium sulphate precipitation, resulting in
improved yield [93,94].
6.1.3. Puriﬁcation of Fab fragments
Monovalent Fab fragments antivenoms have been developed by
some manufacturers [95e97]. They are usually obtained from
sheep hyperimmune plasma. After separation of plasma from blood
cells, immunoglobulins are precipitated by ammonium or sodium
sulphate. The precipitate, containing the IgG fraction, is then dis-
solved in buffered sodium chloride solution at neutral pH. Papain is
added to the Ig solution and a 37 C-18e20 h digestion is performed
[11]. Reaction is stopped by iodoacetamide. The product is diaﬁl-
tered and equilibrated with a buffered isotonic sodium chloride
solution. Afterwards, the preparation is submitted to anion-
exchange chromatography, formulated, sterilized and dispensed in
the ﬁnal containers [10,11,46].6.2. Additional processing steps to improve the purity of
antivenoms
Additional puriﬁcation steps to increase the purity of antivenoms
can be implemented, some of which are already used [10]. For
instance, DEAE-Sepharose or Q-Sepharose Fast Flow anion-
exchange gels or quaternary ammonium cellulose microporous
membranes can be used [90,92,94]. Usually, the conditions are
designed toadsorb contaminants,whereas the activeprinciples pass
through the column or the membrane [10,92]. Anion-exchange
chromatographyhas alsobeensuggested for the removal of bacterial
lipopolysaccharides [98]. The use of afﬁnity chromatography has
been described [99,100]. When venoms are immobilized on chro-
matographic gels and antivenoms are passed through, only anti-
bodies against venom components are retained, greatly increasing
the purity of these preparations and reducing the load of IgGs
directed to non-venom antigens. The use of afﬁnity columns
demands ameticulous validation of the cleaning procedures, aswell
as control of absence of venom ligand leakage; likewise, the condi-
tions for eluting the antibodies may affect their stability. Other
alternatives such as hydrophobic interaction-based membrane
adsorption have been advocated [101]. Research should focus on the
development and adaptation of novel puriﬁcation steps, taking
advantage of developments in the ﬁeld of protein chromatography.
Nevertheless, these studies should include a cost-beneﬁt analysis to
ensure that newproduction steps donot signiﬁcantlyaffect theyield
nor result in excessive increments in the production costs and price
of antivenoms. Economic analyses in the development and design of
antivenoms is needed (see for example [102]).
6.3. Reducing the problem of protein aggregation in antivenoms
Immunoglobulin aggregates have been associated with possible
adverse reactions because of their ability to simulate immune
complexes and activate the complement system [46]. Protein aggre-
gation, leading to turbidity, is common in antivenoms products with
high incidence of adverse reactions [88]. Therefore, manufacturers
should assess fractionation protocols to detect steps that promote
protein instability leading to aggregation. Those may include: (a)
precipitation of IgGs or IgG fragments, followed by an incomplete
solubilization of the precipitate. This might occur when proteins are
precipitated by ammonium salts in salting out procedures; (b) insta-
bility induced by heating, especially during ‘thermocoagulation’; (c)
possible formation of idiotype-anti-idiotype complexes, when using
plasma pools from a large number of individuals, a phenomenon
described in human IgG preparations [103], but not investigated for
antivenoms; (d) effectof excipients onantivenomstability (phenol, for
instance, exerts a denaturing effect on antivenom IgGs [104,105]); and
(e)deﬁcient freeze-dryingprotocols, resulting inprotein stress leading
to aggregation and turbidity. The causes of protein aggregation and
turbidity should be carefully examined by antivenom producers to
optimize fractionation protocols. Likewise, quality control of anti-
venoms should include turbidity testing (see Section 9.1).
6.4. Improving antivenom stability
Snakebite envenoming predominantly occurs in tropical coun-
tries with high temperature and humidity (climatic zone IV).
Antivenoms should be formulated to maintain product character-
istics and guarantee safety and efﬁcacy along shelf-life, including
distribution and storage. The fact that many antivenoms used in
tropical countries are formulated as liquid products, together with
a deﬁcient cold chain system in many areas, represents a problem
that demands consolidated research and development efforts to
generate liquid antivenoms of higher stability. Among several
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to ensure antivenom stability. Freeze-drying is a relatively complex
procedure involving freezing, sublimation and desorption [106].
Although robust methods have been developed and applied for
antivenoms, the thermal stress to which proteins are submitted
during freeze-drying can promote denaturation if the process is not
properly monitored. Efforts should be directed at evaluating and
improving protocols used in the preparation of freeze-dried anti-
venoms, adapting them to each particular product [107]. Likewise,
the need for freeze-dried versus liquid antivenoms calls for careful
case by case analysis since the former have a higher production
cost. In addition, research and development efforts should target
novel liquid antivenom formulations, using various excipients and
pHs, with enhanced protein stability, thus possibly allowing the
storage of liquid antivenoms at temperatures encountered in
tropical regions. This is a research area of great potential, and
promising advances have been made [108,109].
6.5. The issue of preservatives
As indicated in theWHOGuidelines [11], preservatives to prevent
bacterial and fungal contamination should be kept to a minimum
duringplasma storage and fractionation, and shouldnever substitute
any GMPaspect. Phenol and cresols are added to the ﬁnal product by
manymanufacturers [11], especially for liquid formulations [11]. The
potential effect of preservatives on the active substance, or its inter-
actions with excipients, should be carefully analyzed by manufac-
turers. To minimize protein aggregation induced by preservatives,
producers should perform tests of efﬁcacy and determine the
minimal preservative concentration having bacteriostatic activity. In
addition, newpreservative substances generatingminimumstress to
antivenom IgGs should be considered. Optimally, however, manu-
facturers should implement operating procedures and fractionation
protocols able to preventmicrobial contamination, so as to avoid the
need of preservative, as is now the standard in the production of
liquid intramuscular or intravenous human plasma-derived immu-
noglobulin [110]. Decisions to stop the addition of preservatives toStorage and pooling of plasma
Quality control of plasma
Assessment of potency
Pre-clinical and clinical testing
Virus reduction steps
Purification steps
Quality control of antivenom
Fig. 3. Proposed development tasks (circles at right) in hyperimmune plasma storage and
improve quality, safety and efﬁcacy of antivenoms.antivenomsproducts should however carefully consider the possible
virucidal beneﬁts of these compounds, at least on enveloped viruses,
as discussed below. Fig. 3 summarizes themost important tasks that
need to be undertaken for improving the plasma fractionation
protocols and quality control of antivenoms.
6.6. Back to the basics: the need to implement GMP in the
manufacture of antivenoms
For various reasons, some antivenom manufacturers have been
lagging in implementing the basic principles of GoodManufacturing
Practices (GMP). Manufacturers should implement GMP to their
operations, including bleeding protocols, water provision system,
design of laboratories and equipment, sanitation procedures,
manufacturing process, and documentation and training of the staff
involved in all steps of the manufacturing process [11]. A proper
quality assurance of antivenom production should encompass
routine quality control analysis of the in-process products, raw
materials and equipments during fractionation, and all operations
should be traceable. Such analyses are aimed at assessing the
concentration of the active principle and excipients along the
process, as well as preventing possible contamination by microor-
ganisms. In-process controls should prevent failures during manu-
facture and the results should be used to determine the causes of
failures and prevent reoccurrence. Although GMP principles are
outside the scope of this work, international cooperative efforts
should be implemented to help antivenommanufacturers to adhere
to GMP outlined in WHO and other organizations guidelines.
7. Validating the pathogen safety of plasma-derived
antivenoms based on scientiﬁc evidence
7.1. Viruses
There is no report of transmission of viruses, or other zoonotic
diseases, by any animal plasma-derived antivenoms (or other anti-
sera) regardless of their production method [11,111,112]. MostInnovations in cost-effective plasma fractionation
protocols in order to improve recovery, tolerability
and stability of antivenoms
Studies on existing manufacturing
steps for their capacity to inactivate/remove
viruses and other microorganisms
Introduction of novel quality control tests
to ensure immunological and physicochemical
quality
Development of in vitro tests to substitute
currently used in vivo assays for
antivenom potency estimation
Preclinical and clinical assessment of
antivenom efficacy and safety
fractionation, quality control and pre-clinical and clinical assessment (boxes at left) to
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viral reduction steps. As such,whether the apparent safety proﬁle of
antivenoms is due to production processes contributing to robust
viral inactivation or removal, or is a consequence of improper
epidemiological surveillance systems in the countries where these
products are mostly used, is unclear. Increasing scientiﬁc evidence,
however, suggests that several pre-existing puriﬁcation steps of
antivenoms contribute to robust inactivation or removal of viruses.
This possibility is reinforced by the fact that similar steps used in the
manufacture of human IgG products have gone through formal
validation studies demonstrating their robustness for viral reduc-
tion [112]. For instance, caprylic acid treatments used in the
production of F(ab)’2 fragments were found to inactivate/remove
lipid-enveloped viruses [113,114] and some non-enveloped viruses
[114]. Pepsin digestion of plasma at low pH (pH 3.2) to generate
F(ab)’2 can inactivate lipid-enveloped viruses [112,115] andmayalso
affect somenon-envelopedviruses [112].Depth-ﬁltration stepswith
ﬁlter aids to clarify pepsin-digested IgG can remove lipid-enveloped
and non-enveloped viruses [116]. Dedicated heat-treatments in the
liquid state at 58e60 C can inactivate lipid-enveloped viruses and
some non-enveloped viruses [114]. Speciﬁc viral removal steps on
nm-size membranes, known as nanoﬁltration, can ensure robust
removal of viruses [117,118]; this approach could be more readily
used for low molecular mass IgG fragments than for whole IgG.
Phenol and cresol, at 0.25e0.35%, used as preservatives both in
plasma and ﬁnal products are both lipophilic agents and may have,
in principle, the capacity to inactivate lipid-enveloped viruses [11],
potentially contributing to the apparent viral safety proﬁle of anti-
venoms. Recent experimental studies have shown the feasibility of
introducing a dedicated solvent-detergent (S/D) treatment of horse
plasma prior to caprylic acid fractionation of awhole IgG antivenom
used to treat viperid snakebite envenoming [119]. There was no
detrimental impact on the yield, quality and potency of the product
[119], indicating that this technology could possibly be imple-
mented, if needed, to improve the safety of whole IgG antivenoms
against lipid-enveloped viruses. Preliminary experimental evidence
also suggests that a pH 4 treatment of a puriﬁed whole IgG anti-
venoms, as applied to human intravenous IgG [120], can inactivate
lipid-enveloped viruses (Segura et al. in preparation). Finally, the
role potentially played by phenol and cresol in the inactivation of
lipid-enveloped viruses needs to be assessed.
A better understanding of the robustness of existing
manufacturing steps in contributing to viral safety of antivenoms is
needed. This would avoid any potentially unjustiﬁed introduction
of dedicated viral reduction treatments that could affect the
production cost and yield of antivenoms as well as, potentially,
their efﬁcacy. Also, by gaining scientiﬁc understanding of the viral
reduction effects of current manufacturing steps, producers could
ensure their appropriate implementation and monitoring at large-
scale [112], in compliance with GMP. Viral validations studies
following current international guidelines [121] by antivenoms
manufacturers should be strongly encouraged and facilitated. As
manufacturers in developing countries often lack the infrastructure
and know-how to design and perform such validation studies
locally, support from international organizations, regulatory
authorities and experienced Virology laboratories is needed to
validate “generic” production steps of antivenoms and the potential
contribution of phenol and cresol to viral safety.
7.2. Prions
The fact that few antivenoms are from the plasma of ruminant
species, such as sheep, raises the theoretical risk of transmission of
prions. Experimental prion clearance studies by spiking experiments
are encouraged [11], as has been done for human plasmafractionation [122] for a better understanding of the capacity of
sheep-derived antivenoms production steps to remove prion
proteins.
8. Recombinant toxins,monoclonal antibodies and genetically-
engineered antibodies as alternatives for antivenomproduction
The basic methodology for the production of antivenoms, as
outlined above, is likely to remain the predominant manufacturing
platform for many years to come. However, developments in cellular
and molecular biology and genetic engineering may provide novel
tools to improve antivenoms or to develop new product generations.
Some of the areas applicable to antivenommanufacture in the future
are highlighted below:
8.1. Immunization with DNA or with recombinant toxins
The production of antivenoms demands relatively high amounts
of venoms for immunizationandqualitycontrol. Forabundant snake
species, the acquisition of venom is not a problem. However, some
species are difﬁcult to collect and to maintain in captivity, either
because of national conservation policies or because of drastic
reductions in their natural populations. Typical examples are coral
snakes (Micrurus sp) and Lachesis sp in the Americas. Biochemical
and toxinological analyses could lead to the identiﬁcation of the
most relevant toxins, which could be cloned and expressed in
prokaryote or eukaryote systems. Immunization with cDNA encod-
ing for relevant toxins has been explored at the experimental level
with encouraging results [123e125]. Bioinformatic tools canbeused
for the selection of the most appropriate sequences [35].
Recombinant toxins could be used in animal immunization, thus
eliminating the need of animals as source of venom. This alternative
is useful for venoms whose toxicity depends on one or few toxins,
such as the South American rattlesnake Crotalus durissus, whose
toxicity is based primarily on the neuro- andmyotoxic PLA2 crotoxin
and of a thrombin-like serine proteinase [126e128]. Immunization
with these two toxins will likely generate an antivenom effective in
the neutralization of themost relevant toxic effects ofwhole venom.
Similarly, the toxicity of Loxosceles sp spider venom is mostly based
on sphingomyielinaseD. A recombinant enzymehas beengenerated
to produce an antivenom effective in the neutralization of the crude
venom [129]. Investigating further the proteomes of medically-
relevant species of low abundance and difﬁcult acquisition would
allow the identiﬁcation and cloning of their main toxins to generate
recombinant proteins for immunization.
8.2. Monoclonal antibodies
Monoclonal antibodies (MAbs) have been successfully devel-
oped for therapeutic use in various clinical ﬁelds [130,131]. MAbs
with neutralizing capacity against snake venom components have
been generated for various types of toxins [132e138]. The potential
use of this technology relies on successful experimental results
[132]; chimeric or humanized versions of these MAbs may possibly
reduce adverse reactions [139,140]. However, MAbs antivenoms are
likely to have twomain drawbacks: (a) the production cost of these
antibodies is higher than that of polyclonal antibodies, thus
reducing their accessibility to developing countries; (b) most snake
venoms are highly complex mixtures of many different proteins
[141,142], several exerting relevant toxic effects that should be
neutralized by speciﬁc antibodies. In these cases, MAb-based
antivenoms should probably include many MAbs speciﬁc for
different toxins, an issue that complicates their production and
licensing, and increases cost. Nevertheless, it remains to be evalu-
ated whether MAbs could be of beneﬁt against venoms of difﬁcult
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depends on one or few proteins.
8.3. Recombinant and engineered antibodies
Combinatorial antibody generation using molecular cloning
techniques represents a valuable alternative for antivenom gener-
ation. Recombinant single chain Fv antibodies (scFv) have been
successfully generated against various snake venom toxins, and
could neutralize toxic activities of some venom components
[143e147]. A promising alternative is based on recombinant
‘nanobodies’, single domain antibodies comprised by the variable
region of the heavy chain-only camelid IgG [148]. Encouraging
advances have been made for the neutralization of scorpion venom
toxins using nanobodies or scFv [149e151]. A bispeciﬁc construct
against two different types of scorpion venom toxins was effective
in abrogating lethality of the whole venom in mice even when
administered late in the course of envenoming [149]. The potential
use of these recombinant antibodies should be analyzed taking into
account their pharmacokinetic proﬁle and the toxicokinetics of
venom proteins. In general, low molecular mass antibody frag-
ments, such as Fab, scFV, or nanobodies, are rapidly eliminated by
the kidney, thus having a reduced half-life [152,153]. Accordingly,
the use of Fab antivenoms in the treatment of viperid snakebite
envenomings has been associated with recurrence of envenoming
several hours after antivenom administration, a consequence of
their reduced half-life [83,153,154]. A similar scenario will likely
occur in the case of scFv antibodies and nanobodies. However, for
low molecular mass toxins of rapid absorption and high diffusi-
bility, which rapidly reach their targets, such as elapid snake a-
neurotoxins, these low molecular mass antibodies may bind toxins
in the tissues more readily than IgG or F(ab’)2 fragments. It is
important to investigate the potential therapeutic usefulness of
these recombinant antibody fragments in diverse experimental
models of snakebite envenoming to determine whether they could
be effective in the neutralization of low molecular mass, rapidly
acting toxins.
9. Quality control aspects
9.1. Physicochemical analyses
In-process and end-product quality control of antivenoms
requires research and development efforts to further improve their
quality, efﬁcacy and safety. Since the physicochemical characteristics
of antivenoms signiﬁcantly inﬂuence their tolerability [46,58,89],
incorporation of routine assays for physicochemical properties is
necessary. In this regard, the quantiﬁcation of turbidity and high
molecular mass protein aggregates, by turbidimetric and chromato-
graphicanalyses, respectively, shouldbeencouraged (see forexample
[88]). Such analyses are particularly relevant for freeze-dried prepa-
rations, as poorly-controlled freeze-drying generates protein aggre-
gation and turbidity. Novel laboratory assays to quantify excipients
used in antivenom manufacture or formulation are required. Like-
wise, validation of assays used in quality control laboratories should
also be supported. Every laboratory should make efforts towards the
validation of QC procedures, including those of well-established
techniques such as the antivenom potency test [155].
9.2. Substitution of in vivo tests by in vitro assays
Assessment of antivenom potency still relies on traditional
mouse lethality assay, the gold standard for ensuring the pre-
clinical neutralizing efﬁcacy of antivenoms [11]. Nevertheless, this
assay leads to animal suffering due to the toxic effects (in particularpain) induced by venoms. Preclinical tests to assess the control of
hemorrhage, myonecrosis, deﬁbrination and edema also involves
animal models [11,30]. The development of in vitro assays to
substitute for animal models is a highly relevant task for future
development of antivenom quality control as a way to achieve the
‘three R’ goals of animal experimentation, i.e. Reduce, Reﬁne and
Replace animal tests [156].
The biochemical and toxicological complexity of snake venoms
greatly complicates the search for substitutive in vitro tests.
Snakebite envenomings are complex pathophysiological processes
often involving the simultaneous action of various types of toxins,
thus representing a complex scenario that requires an integrative
approach for a proper understanding [157]. In this context, the
development of in vitro tests should ideally be based on a careful
analysis of the predominant toxic proteins present in a particular
venom, and on the understanding of the mechanisms by which
these toxins exert their deleterious effects. A number of studies
have succeeded at implementing in vitro tests giving a good
correlation with the in vivo lethality assay. They include enzyme
immunoassays [158e160], although some other enzyme immu-
noassays show a poor correlation with lethality tests [161,162]. For
crude venoms, and since these assays detect antibodies against all
venom components regardless of their role in toxicity, the reac-
tivity against some highly immunogenic venom proteins, devoid of
toxicity, may give high absorbance values not related with the
neutralizing potency. Other studies have focused on the neutrali-
zation of venom activities, such as indirect hemolysis, i.e. phos-
pholipase A2 activity [163]. Some workers have implemented in
vitro assays which assess neurotoxicity and myotoxicity in nerve-
muscle preparations [164,165]. The use of cell culture systems to
study cytotoxic venoms activity is an alternative for necrotizing
venoms, e.g. from many viperid and some elapid species [166,167].
Fertile hen’s eggs have also been used for assessing venom toxicity
and antivenom potency, since despite being in vivo assays, these
tests are performed at a stage in neurological development when
pain sensation has not appeared yet [168,169].
The complexity and diversity of the pathophysiology of snake-
bite envenoming demand careful case by case analysis of medi-
cally-relevant venoms to design the most appropriate assays for
assessing antivenom neutralizing ability. In some cases, the toxicity
of a venom is based on a single toxin or a group of few toxins. This is
likely the case of some elapid venoms [170] whose toxicity is based
predominantly on the action of neurotoxins. On the other hand, the
toxicity of some viperid venoms largely relies on the systemic
action of P-III metalloproteinases, such as in the case of Echis
ocellatus, which contain potent hemorrhagic and procoagulant
metalloproteinases [171] and some Bothrops sp venoms [20,172].
When the key lethal toxin is identiﬁed, then the ability of an
antivenom to react or neutralize this toxin is likely to correlate with
the neutralization of lethality. A good example is crotoxin. This
dimeric phospholipase A2 is responsible for three of the most
conspicuous clinical manifestations in envenomings by subspecies
of the South American rattlesnake, i.e. neurotoxicity, systemic
myotoxicity and renal failure [126,128]. Therefore, an immunoassay
to detect antibodies against crotoxin, or a test designed to assess
the neutralization of its phospholipase A2 activity, are likely to
correlate with the in vivo toxicity of this toxin and of the whole
venom. In the case of venoms whose toxicity greatly depends on
metalloproteinases, an immunoassay to detect antibody titer
against the most abundant metalloproteinase, or a functional test
to assess the neutralization of proteolytic activity of the enzyme,
are likely to correlate with the neutralization of lethality. However,
in many other cases, toxicity results from the combined action of
different types of toxins acting synergistically. For instance, the
lethality induced by the venoms of many viperid snakes seems to
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loproteinases, phospholipases A2 and serine proteinases [173]. This
greatly complicates the development of in vitro tests substitutive to
the mouse lethality assay.
The complexity of this issue underscores the relevance of per-
forming biochemical, proteomic and toxicological characterizations
of venoms of species that inﬂict a high toll of snakebites in the
world and which are used as immunogens for antivenom produc-
tion. International cooperative research efforts should be under-
taken to have a complete characterization of these venoms, some of
which have already been studied in detail. With this information at
hand, it would be possible to design in vitro methods to assess the
neutralization of these venoms by antivenoms. Although it is likely
that the mouse lethality assay will continue to be the gold standard
for the ﬁnal quality control of the potency of antivenoms,
adequately validated in vitro tests should be introduced for
assessing antivenom antibody titre in immunized horses as well as
for in-process quality control. This would greatly reduce the use
and suffering of animals in antivenom production.
10. The need for pre-clinical and clinical assessments in
antivenom development
As clearly stated in theWHO guidelines [11], the development of
new antivenoms and the introduction of currently approved anti-
venoms to new regions demand careful pre-clinical and clinical
assessment of efﬁcacy and safety. A series of laboratory tests has
been developed to determine the neutralizing capacity of anti-
venoms against the most relevant toxic activities of snake venoms
[11]. Collaborative research projects are mandatory to properly
assess the pre-clinical efﬁcacy of currently available antivenoms
and of new antivenoms, as has been done in Latin America [32].
There is a crucial need to develop local capacity in many countries
to collect venom from indigenous snakes in order to prepare pools
for use not only for themanufacture of antivenoms, either locally or
abroad, but also for pre-clinical assessment of the efﬁcacy of anti-
venoms distributed in those countries. On the other hand, the
introduction of new antivenoms for clinical use requires a meticu-
lous clinical assessment of efﬁcacy and safety through well-
designed clinical trials [11]. This arena of pre-clinical and clinical
testing of antivenoms should be based on international collabora-
tive efforts that take advantage of the expertise developed by
a number of groups in these ﬁelds.
11. Concluding remarks: the need to promote innovation in
the context of international networking and cooperation
A number of areas demanding technological innovation in anti-
venom production and quality control have been highlighted in this
work. Antivenom production is largely within the scope of public
and private laboratories in developing countries, and antivenoms
are largely distributed and used in countries of Africa, Asia, Latin
America andOceania. Consequently, careful consideration shouldbe
given to the economic aspects of antivenom manufacture and
marketing, since their price should remainaffordable topatients and
public health systems in developing countries. Therefore, a careful
cost-beneﬁt analysis has to be done when introducing new
manufacturing steps. Innovation programs aim at improving anti-
venoms on the basis of low cost interventions should be prioritised.
Future innovation in antivenom production and quality control
should include concerted efforts on taxonomy, epidemiology and
clinical research, proteomics and transcriptomics, pharmacology,
immunology, veterinarymedicine,plasmafractionation technologies,
process engineering, and quality control tests, among others
(Figs.1e3). Such complex disciplinary landscape necessarily requiresthe collaboration of groups working in different areas and different
countries/regions. In particular, well-established and emerging
production laboratories located in developing countries need to
promote links with research and production groups in both devel-
oping and developed countries to circumvent their limitations and
potentiate their strengths. The expertise gained by consolidated
manufacturing groups should help less developed laboratories
through a number of mechanisms involving technology transfer
programs, training activities, exchanges, and workshops, using
information and communication technologies to foster these inter-
actions, along the growing networking trend in many scientiﬁc and
technological ﬁelds [174]. Partnerships of different sorts, involving
both southesouth and southenorth cooperation, and the participa-
tion of the WHO and non-governmental groups, like the Global
Snakebite Initiative [175] and international foundations, should play
a leading role inpromoting these initiatives. Likewise, theopenaccess
to novel developments within this ﬁeld should be encouraged. In
summary, an active process of innovation and development of anti-
venoms needs to be encouraged, in a frame of international coordi-
nation, cooperation and networking. In the long term, these efforts,
together with other actions in the public health realm, will greatly
contribute to alleviate the burden of human suffering provoked by
snakebite envenoming.
Acknowledgements
Many of the ideas presented in this work have been discussed
with colleagues in many parts of the world. J.M.G. and G.L. thank
their colleagues of Instituto Clodomiro Picado and of laboratories in
Latin America and abroad who have provided stimulus and ideas
for the improvement of antivenoms. Some of the ﬁndings discussed
are the result of projects supported by Vicerrectoría de Inves-
tigación (Universidad de Costa Rica), CRUSA-CSIC, the International
Foundation for Science (IFS), and the program CYTED.
References
[1] Gutiérrez JM, Theakston RD, Warrell DA. Confronting the neglected problem
of snake bite envenoming: the need for a global partnership. PLoS Med
2006;3:e150.
[2] Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG. Snake
envenoming: a disease of poverty. PLoS Negl Trop Dis 2009;3:e569.
[3] WHO. Rabies and envenomings. A neglected public health issue. Geneva:
World Health Organization; 2007.
[4] Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK,
Pathmeswaran A, Premaratna R, et al. The global burden of snakebite:
a literature analysis and modelling based on regional estimates of enve-
noming and deaths. PLoS Med 2008;5:e218.
[5] Bon C. Serum therapy was discovered 100 years ago. In: Bon C, Goyffon M,
editors. Envenomings and their treatments. Lyon: Editions Fondation Marcel
Mérieux; 1996. p. 3e9.
[6] Rojas G, Jiménez JM, Gutiérrez JM. Caprylic acid fractionation of hyperim-
mune horse plasma: description of a simple procedure for antivenom
production. Toxicon 1994;32:351e63.
[7] Bolaños R. Antivenenos. In: Organización Panamericana de la Salud, editor.
Manual de Procedimientos: Producción y Pruebas de Control en la Prepar-
ación de Antisueros Diftérico, Tetánico, Botulínico, Antivenenos y de la
Gangrena Gaseosa; 1977. p. 104e41. Washington.
[8] Raw I, Guidolin R, Higashi HG, Kelen EMA. Antivenins in Brazil: preparation.
In: Tu AT, editor. Handbook of natural toxins. New York: Marcel Dekker;
1991. p. 557e81.
[9] Grandgeorge M, Véron JL, Lutsch C, Makula MF, Riffard P, Pépin S, et al.
Preparation of improved F(ab’)2 antivenoms. An example: new polyvalent
European viper antivenom (equine). In: Bon C, Goyffon M, editors. Enve-
nomings and their treatments. Lyon: Fondation Marcel Mérieux; 1996. p.
161e72.
[10] Al-Abdulla I, Garnvwa JM, Rawat S, Smith DS, Landon J, Nasidi A. Formulation
of a liquid ovine Fab-based antivenom for the treatment of envenomation by
the Nigerian carpet viper (Echis ocellatus). Toxicon 2003;42:399e404.
[11] WHO. WHO Guidelines for the production, control and regulation of snake
antivenom immunoglobulins 2010 World Health Organization Geneva
[12] Chippaux JP, Williams V, White J. Snake venom variability: methods of study,
results and interpretation. Toxicon 1991;29:1279e303.
J.M. Gutiérrez et al. / Biologicals 39 (2011) 129e142 139[13] Boldrini-Franca J, Correa-Netto C, Silva MM, Rodrigues RS, De La
Torre P, Pérez A, et al. Snake venomics and antivenomics of Crotalus
durissus subspecies from Brazil: assessment of geographic variation and
its implication on snakebite management. J Proteomics 2010;73:
1758e76.
[14] Gutiérrez JM, León G, Lomonte B, Angulo Y. Antivenoms for the treatment of
snakebite envenomings. Curr Immunol Rev, in press.
[15] Fox JW, Serrano SM. Exploring snake venom proteomes: multifaceted anal-
yses for complex toxin mixtures. Proteomics 2008;8:909e20.
[16] Gutiérrez JM, Lomonte B, León G, Alape-Girón A, Flores-Díaz M, Sanz L, et al.
Snake venomics and antivenomics: proteomic tools in the design and control
of antivenoms for the treatment of snakebite envenoming. J Proteomics
2009;72:165e82.
[17] Calvete JJ, Sanz L, Angulo Y, Lomonte B, Gutiérrez JM. Venoms, venomics,
antivenomics. FEBS Lett 2009;583:1736e43.
[18] Currier RB, Harrison RA, Rowley PD, Laing GD, Wagstaff SC. Intra-speciﬁc
variation in venom of the African Puff Adder (Bitis arietans): differential
expression and activity of snake venom metalloproteinases (SVMPs). Tox-
icon 2010;55:864e73.
[19] Prasad NB, Uma B, Bhatt SK, Gowda VT. Comparative characterisation of
Russell’s viper (Daboia/Vipera russelli) venoms from different regions of the
Indian peninsula. Biochim Biophys Acta 1999;1428:121e36.
[20] Núñez V, Cid P, Sanz L, De La Torre P, Angulo Y, Lomonte B, et al. Snake
venomics and antivenomics of Bothrops atrox venoms from Colombia and the
Amazon regions of Brazil, Peru and Ecuador suggest the occurrence of
geographic variation of venom phenotype by a trend towards paedomor-
phism. J Proteomics 2009;73:57e78.
[21] Lanari LC, Rosset S, González ME, Liria N, de Roodt AR. A study on the venom
of Bothrops alternatus Dumeril, Bibron and Dumeril, from different regions of
Argentina. Toxicon 2010;55:1415e24.
[22] Mackessy SP. Evolutionary trends in venom composition in the western
rattlesnakes (Crotalus viridis sensu lato): toxicity vs. tenderizers. Toxicon
2010;55:1463e74.
[23] Ferquel E, de Haro L, Jan V, Guillemin I, Jourdain S, Teynie A, et al. Reappraisal
of Vipera aspis venom neurotoxicity. PLoS One 2007;2:e1194.
[24] Calvete JJ, Sanz L, Cid P, de la Torre P, Flores-Díaz M, Dos Santos MC, et al.
Snake venomics of the Central American rattlesnake Crotalus simus and the
South American Crotalus durissus complex points to neurotoxicity as an
adaptive paedomorphic trend along Crotalus dispersal in South America.
J Proteome Res 2010;9:528e44.
[25] Saravia P, Rojas E, Arce V, Guevara C, López JC, Chaves E, et al. Geographic
and ontogenic variability in the venom of the neotropical rattlesnake Cro-
talus durissus: pathophysiological and therapeutic implications. Rev Biol Trop
2002;50:337e46.
[26] Gutiérrez JM, dos Santos MC, Furtado MFD, Rojas G. Biochemical and phar-
macological similarities between the venoms of newborn Crotalus durissus
durissus and adult Crotalus durissus terriﬁcus rattlesnakes. Toxicon
1991;29:1273e7.
[27] Warrell DA. Snakebites in Central and South America: epidemiology, clinical
features, and clinical management. In: Campbell JA, Lamar WW, editors. The
venomous reptiles of the western hemisphere. Ithaca: Cornell University
Press; 2004. p. 709e61.
[28] Schenberg S. Geographical pattern of crotamine distribution in the same
rattlesnake subspecies. Science 1959;129:1361e3.
[29] Calvete JJ. Antivenomics and venom phenotyping: a marriage of convenience
to address the performance and range of clinical use of antivenoms. Toxicon
2010;56:1284e91.
[30] Anonymous. Determinación de Actividades Tóxicas de Venenos de Ser-
pientes y su Neutralización por Antivenenos. Manual de Métodos de Labo-
ratorio. San José: Instituto Clodomiro Picado; 2008.
[31] Calvete JJ, Cid P, Sanz L, Segura A, Villalta M, Herrera M, et al. Antivenomic
assessment of the immunological reactivity of EchiTAb-Plus-ICP, an anti-
venom for the treatment of snakebite envenoming in sub-Saharan Africa. Am
J Trop Med Hyg 2010;82:1194e201.
[32] Segura A, Castillo MC, Núñez V, Yarlequé A, Gonçalves LR, Villalta M, et al.
Preclinical assessment of the neutralizing capacity of antivenoms produced
in six Latin American countries against medically-relevant Bothrops snake
venoms. Toxicon 2010;56:980e9.
[33] Dias-da-Silva W, Guidolin R, Raw I, Higashi HG, Caricati CP, Morais JF, et al.
Cross-reactivity of horse monovalent antivenoms to venoms of ten Bothrops
species. Mem Inst Butantan 1989;51:153e68.
[34] Harrison RA. Development of venom toxin-speciﬁc antibodies by DNA
immunisation: rationale and strategies to improve therapy of viper enve-
noming. Vaccine 2004;22:1648e55.
[35] Wagstaff SC, Laing GD, Theakston RD, Papaspyridis C, Harrison RA. Bio-
informatics and multiepitope DNA immunization to design rational snake
antivenom. PLoS Med 2006;3:e184.
[36] Gutiérrez JM, Rojas E, Quesada L, León G, Núñez J, Laing GD, et al. Pan-African
polyspeciﬁc antivenom produced by caprylic acid puriﬁcation of horse IgG:
an alternative to the antivenom crisis in Africa. Trans R Soc Trop Med Hyg
2005;99:468e75.
[37] Ariaratnam CA, Thuraisingam V, Kularatne SA, Sheriff MH, Theakston RD, de
Silva A, et al. Frequent and potentially fatal envenoming by hump-nosed pit
vipers (Hypnale hypnale and H. nepa) in Sri Lanka: lack of effective anti-
venom. Trans R Soc Trop Med Hyg 2008;102:1120e6.[38] Trinh KX, Khac QL, Trinh LX, Warrell DA. Hyponatraemia, rhabdomyolysis,
alterations in blood pressure and persistent mydriasis in patients enve-
nomed by Malayan kraits (Bungarus candidus) in southern Viet Nam. Toxicon
2010;56:1070e5.
[39] Thomas L, Tyburn B, Bucher B, Pecout F, Ketterle J, Rieux D, et al. Prevention
of thromboses in human patients with Bothrops lanceolatus envenoming in
Martinique: failure of anticoagulants and efﬁcacy of a monospeciﬁc anti-
venom. Research Group on Snake Bites in Martinique. Am J Trop Med Hyg
1995;52:419e26.
[40] Warrell DA. Clinical toxicology of snakebite in Asia. In: Meier J, White J,
editors. Handbook of clinical toxicology of animal venoms and poisons. Boca
Raton: CRC Press; 1995. p. 493e594.
[41] Quijada-Mascareñas A, Wüster W. Recent advances in venomous snake
systematics In: Mackessy SP, editor. Handbook of venoms and toxins of
reptiles Boca Raton: CRC Press. p. 25e64.
[42] Wüster W, Golay P, Warrell DA. Synopsis of recent developments in
venomous snake systematics. Toxicon 1997;35:319e40.
[43] León G, Sánchez L, Hernández A, Villalta M, Herrera M, Segura A, et al.
Immune response towards snake venoms. Curr Immunol Rev, in press.
[44] Lalloo DG, Theakston RD. Snake antivenoms. J Toxicol Clin Toxicol
2003;41:277e90. 317e27.
[45] Gutiérrez JM, Higashi HG, Fan HW, Burnouf T. Strengthening antivenom
production in Central and South American public laboratories: report of
a workshop. Toxicon 2007;49:30e5.
[46] Gutiérrez JM, León G. Snake antivenoms: Technological, clinical and public
health issues. In: de Lima ME, Pimenta AMC, Martin-Euclaire MF, Zingalli RB,
Rochat H, editors. Animal toxins: state of the art perspectives in health and
biotechnology. Belo Horizonte: Editora UFMG; 2009. p. 393e421.
[47] Cook DA, Owen T, Wagstaff SC, Kinne J, Wernery U, Harrison RA. Analysis of
camelid IgG for antivenom development: serological responses of venom-
immunised camels to prepare either monospeciﬁc or polyspeciﬁc anti-
venoms for West Africa. Toxicon 2010;56:363e72.
[48] Fernández GP, Segura A, Herrera M, Velasco W, Solano G, Gutiérrez JM, et al.
Neutralization of Bothrops mattogrossensis snake venom from Bolivia:
experimental evaluation of llama and donkey antivenoms produced by
caprylic acid precipitation. Toxicon 2010;55:642e5.
[49] Carroll SB, Thalley BS, Theakston RD, Laing G. Comparison of the purity and
efﬁcacy of afﬁnity puriﬁed avian antivenoms with commercial equine cro-
talid antivenoms. Toxicon 1992;30:1017e25.
[50] Almeida CM, Kanashiro MM, Rangel Filho FB, Mata MF, Kipnis TL, da Silva WD.
Development of snake antivenom antibodies in chickens and their puriﬁcation
from yolk. Vet Rec 1998;143:579e84.
[51] Meenatchisundaram S, Parameswari G, Michael A, Ramalingam S. Studies on
pharmacological effects of Russell’s viper and saw-scaled viper venom and
its neutralization by chicken egg yolk antibodies. Int Immunopharmacol
2008;8:1067e73.
[52] Araujo AS, Lobato ZI, Chavez-Olortegui C, Velarde DT. Brazilian IgY-Bothrops
antivenom: studies on the development of a process in chicken egg yolk.
Toxicon 2010;55:739e44.
[53] Cook DA, Samarasekara CL, Wagstaff SC, Kinne J, Wernery U, Harrison RA.
Analysis of camelid IgG for antivenom development: immunoreactivity and
preclinical neutralisation of venom-induced pathology by IgG subclasses,
and the effect of heat treatment. Toxicon 2010;56:596e603.
[54] Sheoran AS, Holmes MA. Separation of equine IgG subclasses (IgGa, IgGb and
IgG(T)) using their differential binding characteristics for staphylococcal
protein A and streptococcal protein G. Vet Immunol Immunopathol
1996;55:33e43.
[55] Fernandes I, Takehara HA, Mota I. Isolation of IgGT from hyperimmune horse
anti-snake venom serum: its protective ability. Toxicon 1991;29:1373e9.
[56] de Simone E, Saccodossi N, Ferrari A, Leoni L, Leoni J. Immunochemical
analysis of IgG subclases and IgM in south American camelids. Small Rumin
Res 2006;64:2e9.
[57] Sevcik C, Diaz P, D’Suze G. On the presence of antibodies against bovine,
equine and poultry immunoglobulins in human IgG preparations, and its
implications on antivenom production. Toxicon 2008;51:10e6.
[58] Herrera M, León G, Segura A, Meneses F, Lomonte B, Chippaux JP, et al.
Factors associated with adverse reactions induced by caprylic acid-frac-
tionated whole IgG preparations: comparison between horse, sheep and
camel IgGs. Toxicon 2005;46:775e81.
[59] Sjostrom L, Al-Abdulla IH, Rawat S, Smith DC, Landon J. A comparison of
ovine and equine antivenoms. Toxicon 1994;32:427e33.
[60] Landon J, Smith DC. Merits of sheep antisera for antivenom manufacture.
J Toxicol Toxin Rev 2003;22:15e22.
[61] Abubakar IS, Abubakar SB, Habib AG, Nasidi A, Durfa N, Yusuf PO, et al.
Randomised controlled double-blind non-inferiority trial of two antivenoms
for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria. PLoS
Negl Trop Dis 2010;4:e767.
[62] Feige K, Ehrat FB, Kastner SB, Schwarzwald CC. Automated plasmapheresis
compared with other plasma collection methods in the horse. J Vet Med A
Physiol Pathol Clin Med 2003;50:185e9.
[63] Camey KU, Velarde DT, Sanchez EF. Pharmacological characterization and
neutralization of the venoms used in the production of Bothropic antivenom
in Brazil. Toxicon 2002;40:501e9.
[64] Sousa JR, Monteiro RQ, Castro HC, Zingali RB. Proteolytic action of Bothrops
jararaca venom upon its own constituents. Toxicon 2001;39:787e92.
J.M. Gutiérrez et al. / Biologicals 39 (2011) 129e142140[65] Hati RN, Mandal M, Hati AK. Active immunization of rabbit with gamma
irradiated Russell’s viper venom toxoid. Toxicon 1990;28:895e902.
[66] León G, Estrada R, Chaves F, Rojas G, Ovadia M, Gutiérrez JM. Inhibition by
CaNa2EDTA of local tissue damage induced by Bothrops asper (terciopelo)
venom: application in horse immunization for antivenom production. Tox-
icon 1998;36:321e31.
[67] Clissa PB, do Nascimento N, Rogero JR. Toxicity and immunogenicity of
Crotalus durissus terriﬁcus venom treated with different doses of gamma rays.
Toxicon 1999;37:1131e41.
[68] Tang Y, Dong W, Kong T. Effects of heating on the immunogenicity and
biological toxicity of Deinagkistrodon acutus venom and its fractions. Toxicon
2010;56:45e54.
[69] Stephano MA, Guidolin R, Higashi HG, Tambourgi DV, Sant’Anna OA. The
improvement of the therapeutic anti-Lachesis muta serum production in
horses. Toxicon 2005;45:467e73.
[70] Rangel-Santos A, Lima C, Lopes-Ferreira M, Cardoso DF. Immunosuppressive
role of principal toxin (crotoxin) of Crotalus durissus terriﬁcus venom. Tox-
icon 2004;44:609e16.
[71] Sampaio SC, Rangel-Santos AC, Peres CM, Curi R, Cury Y. Inhibitory effect of
phospholipase A2 isolated from Crotalus durissus terriﬁcus venom on
macrophage function. Toxicon 2005;45:671e6.
[72] Stills Jr HF. Adjuvants and antibody production: dispelling the myths asso-
ciated with Freund’s complete and other adjuvants. ILAR J 2005;46:280e93.
[73] Gutiérrez JM, Chaves F, Rojas E, Elizondo J, Avila C, Cerdas L. Production of
monovalent anti-Bothrops asper antivenom: development of immune
response in horses and neutralizing ability. Rev Biol Trop 1988;36:511e7.
[74] New RR, Theakston RD, Zumbuhl O, Iddon D, Friend J. Immunization against
snake venoms. N Engl J Med 1984;311:56e7.
[75] Waghmare A, Deopurkar RL, Salvi N, Khadilkar M, Kalolikar M, Gade SK.
Comparison of Montanide adjuvants, IMS 3012 (nanoparticle), ISA 206 and
ISA 35 (Emulsion based) along with incomplete Freund’s adjuvant for
hyperimmunization of equines used for production of polyvalent snake
antivenom. Vaccine 2009;27:1067e72.
[76] Bolaños R, Cerdas L. Producción y control de sueros antiofídicos en Costa Rica
Bol Of Sanit Panam, 1980; 88: 189e96.
[77] Russell FE. Snake venom immunology: historical and practical consider-
ations. J Toxicol Toxin Rev 1988;7:1e82.
[78] Freitas TV, Fortes-Dias CL, Diniz CR, Velarde DT, Freitas CF. Immunization of
horses with Crotalus durissus terriﬁcus (South American rattlesnake) venom.
A comparison of four different procedures. Braz J Med Biol Res 1991;
24:281e90.
[79] Chotwiwatthanakun C, Pratanaphon R, Akesowan S, Sriprapat S,
Ratanabanangkoon K. Production of potent polyvalent antivenom against
three elapid venoms using a low dose, low volume, multi-site immunization
protocol. Toxicon 2001;39:1487e94.
[80] Chippaux JP, Lang J, Eddine SA, Fagot P, Rage V, Peyrieux JC, et al. Clinical
safety of a polyvalent F(ab’)2 equine antivenom in 223 African snake enve-
nomations: a ﬁeld trial in Cameroon. Trans R Soc Trop Med Hyg
1998;92:657e62.
[81] Cardoso JL, Fan HW, Franca FO, Jorge MT, Leite RP, Nishioka SA, et al.
Randomized comparative trial of three antivenoms in the treatment of
envenoming by lance-headed vipers (Bothrops jararaca) in Sao Paulo, Brazil.
Q J Med 1993;86:315e25.
[82] Otero-Patiño R, Cardoso JL, Higashi HG, Núñez V, Díaz A, Toro MF, et al.
A randomized, blinded, comparative trial of one pepsin-digested and two
whole IgG antivenoms for Bothrops snake bites in Uraba, Colombia. Am J Trop
Med Hyg 1998;58:183e9.
[83] Ariaratnam CA, Sjostrom L, Raziek Z, Kularatne SA, Arachchi RW, Sheriff MH,
et al. An open, randomized comparative trial of two antivenoms for the
treatment of envenoming by Sri Lankan Russell’s viper (Daboia russelii rus-
selii). Trans R Soc Trop Med Hyg 2001;95:74e80.
[84] LoVecchio F, Klemens J, Roundy EB, Klemens A. Serum sickness following
administration of antivenin (Crotalidae) polyvalent in 181 cases of presumed
rattlesnake envenomation. Wilderness Environ Med 2003;14:220e1.
[85] Chippaux JP, Massougbodji A, Stock RP, Alagón A. Clinical trial of an F(ab’)2
polyvalent equine antivenom for African snake bites in Benin. Am J Trop Med
Hyg 2007;77:538e46.
[86] Premawardhena AP, de Silva CE, Fonseka MM, Gunatilake SB, de Silva HJ.
Low dose subcutaneous adrenaline to prevent acute adverse reactions to
antivenom serum in people bitten by snakes: randomised, placebo
controlled trial. BMJ 1999;318:1041e3.
[87] Gawarammana IB, Kularatne SA, Dissanayake WP, Kumarasiri RP,
Senanayake N, Ariyasena H. Parallel infusion of hydrocortisone þ/ chlor-
pheniramine bolus injection to prevent acute adverse reactions to anti-
venom for snakebites. Med J Aust 2004;180:20e3.
[88] Otero R, Gutiérrez JM, Rojas G, Nuñez V, Diaz A, Miranda E, et al.
A randomized blinded clinical trial of two antivenoms, prepared by caprylic
acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium
snake bites in Colombia: correlation between safety and biochemical char-
acteristics of antivenoms. Toxicon 1999;37:895e908.
[89] León G, Monge M, Rojas E, Lomonte B, Gutiérrez JM. Comparison between
IgG and F(ab’)2 polyvalent antivenoms: neutralization of systemic effects
induced by Bothrops asper venom in mice, extravasation to muscle tissue,
and potential for induction of adverse reactions. Toxicon 2001;39:793e801.[90] León G, Lomonte B, Gutiérrez JM. Anticomplementary activity of equine
whole IgG antivenoms: comparison of three fractionation protocols. Toxicon
2005;45:123e8.
[91] Otero R, León G, Gutiérrez JM, Rojas G, Toro MF, Barona J, et al. Efﬁcacy and
safety of two whole IgG polyvalent antivenoms, reﬁned by caprylic acid
fractionation with or without beta-propiolactone, in the treatment of
Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg 2006;
100:1173e82.
[92] Jones RG, Landon J. A protocol for ‘enhanced pepsin digestion’: a step by step
method for obtaining pure antibody fragments in high yield from serum.
J Immunol Methods 2003;275:239e50.
[93] dos Santos MC, D’Imperio Lima MR, Furtado GC, Colletto GM, Kipnis TL, Dias
da Silva W. Puriﬁcation of F(ab’)2 anti-snake venom by caprylic acid: a fast
method for obtaining IgG fragments with high neutralization activity, purity
and yield. Toxicon 1989;27:297e303.
[94] Raweerith R, Ratanabanangkoon K. Fractionation of equine antivenom using
caprylic acid precipitation in combination with cationic ion-exchange
chromatography. J Immunol Methods 2003;282:63e72.
[95] Smith DC, Reddi KR, Laing G, Theakston RG, Landon J. An afﬁnity puriﬁed
ovine antivenom for the treatment of Vipera berus envenoming. Toxicon
1992;30:865e71.
[96] Laing GD, Lee L, Smith DC, Landon J, Theakston RD. Experimental assessment
of a new, low-cost antivenom for treatment of carpet viper (Echis ocellatus)
envenoming. Toxicon 1995;33:307e13.
[97] Landon J, Smith DC. Development of novel antivenoms based on speciﬁc
ovine Fab. In: Bon C, Goyffon M, editors. Envenomings and their treatments.
Lyon: Editions Fondation Marcel Mérieux; 1996. p. 173e80.
[98] Lee SH, Kim JS, Kim CW. Optimization of buffer conditions for the removal of
endotoxins using Q-Sepharose. Process Biochem 2003;38:1091e8.
[99] Russell FE, Sullivan JB, Egen NB, Jeter WS, Markland FS, Wingert WA, et al.
Preparation of a new antivenin by afﬁnity chromatography. Am J Trop Med
Hyg 1985;34:141e50.
[100] Dart RC, Seifert SA, Carroll L, Clark RF, Hall E, Boyer-Hassen LV, et al. Afﬁnity-
puriﬁed, mixed monospeciﬁc crotalid antivenom ovine Fab for the treatment
of crotalid venom poisoning. Ann Emerg Med 1997;30:33e9.
[101] Wang L, Sun X, Ghosh R. Puriﬁcation of equine IgG using membrane based
enhanced hybrid bioseparation technique: a potential method for
manufacturing hyperimmune antibody. Biotechnol Bioeng 2008;99:625e33.
[102] Morais V, Massaldi H. Economic evaluation of snake antivenom production
in the public system. J Venom Anim Toxins incl Trop Dis 2006;12:497e511.
[103] Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron
microscopic and immunologic analyses of spontaneous idiotype-anti-idiot-
ype dimers in pooled human IgG. J Immunol 1990;144:1387e95.
[104] Rojas G, Vargas M, Robles A, Gutiérrez JM. Turbidity of hyperimmune equine
antivenom: the role of phenol and serum lipoproteins. Toxicon 1993;
31:61e6.
[105] García M, Monge M, León G, Lizano S, Segura E, Solano G, et al. Effect of
preservatives on IgG aggregation, complement-activating effect and hypo-
tensive activity of horse polyvalent antivenom used in snakebite enveno-
mation. Biologicals 2002;30:143e51.
[106] Wang W. Lyophilization and development of solid protein pharmaceuticals.
Int J Pharm 2000;203:1e60.
[107] Tsinontides SC, Rajniak P, Pham D, Hunke WA, Placek J, Reynolds SD. Freeze
dryingeprinciples and practice for successful scale-up to manufacturing. Int J
Pharm 2004;280:1e16.
[108] Rodrigues-Silva R, Antunes GF, Velarde DT, Santoro MM. Thermal stability
studies of hyperimmune horse antivenoms. Toxicon 1999;37:33e45.
[109] Segura A, Herrera M, González E, Vargas M, Solano G, Gutiérrez JM, et al.
Stability of equine IgG antivenoms obtained by caprylic acid precipitation:
towards a liquid formulation stable at tropical room temperature. Toxicon
2009;53:609e15.
[110] Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in
production methods, quality control and quality assurance. Vox Sang
2010;98:12e28.
[111] Theakston RD, Warrell DA, Grifﬁths E. Report of a WHO workshop on the
standardization and control of antivenoms. Toxicon 2003;41:541e57.
[112] Burnouf T, Grifﬁths E, Padilla A, Seddik S, Stephano MA, Gutiérrez JM.
Assessment of the viral safety of antivenoms fractionated from equine
plasma. Biologicals 2004;32:115e28.
[113] Burnouf T, Terpstra F, Habib G, Seddik S. Assessment of viral inactivation
during pH 3.3 p.psin digestion and caprylic acid treatment of antivenoms.
Biologicals 2007;35:329e34.
[114] Mpandi M, Schmutz P, Legrand E, Duc R, Geinoz J, Henzelin-Nkubana C, et al.
Partitioning and inactivation of viruses by the caprylic acid precipitation
followed by a terminal pasteurization in the manufacturing process of horse
immunoglobulins. Biologicals 2007;35:335e41.
[115] Lazar A, Epstein E, Lustig S, Barnea A, Silberstein L, Reuveny S. Inactivation of
West-Nile virus during peptic cleavage of horse plasma IgG. Biologicals
2002;30:163e5.
[116] Cameron-Smith R, Miloradovic L, Cheyne I, Healy K. The removal of viruses
during the puriﬁcation of equine antisera using ﬁltration aids Hyﬂo Super-
Cel and Fulmon Super A. Biologicals 2000;28:169e74.
[117] Burnouf T, Radosevich M. Nanoﬁltration of plasma-derived bio-
pharmaceutical products. Haemophilia 2003;9:24e37.
J.M. Gutiérrez et al. / Biologicals 39 (2011) 129e142 141[118] Burnouf T, Radosevich M, Goubran HA, Willkommen H. Place of nano-
ﬁltration for assuring viral safety of biologicals. Curr Nanoscience
2005;1:189e201.
[119] Segura A, León G, Su CY, Gutiérrez JM, Burnouf T. Assessment of the impact of
solvent/detergent treatment on the quality and potency of a whole IgG
equine antivenom. Biologicals 2009;37:306e12.
[120] Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007;21:101e17.
[121] WHO Guidelines on viral inactivation and removal procedures intended to
assure the viral safety of human blood plasma products Geneva www.WHO.
int/bloodproducts 2003.
[122] Burnouf T, Padilla A. Current strategies to prevent transmission of prions by
human plasma derivatives. Transfus Clin Biol 2006;13:320e8.
[123] Harrison RA, Moura-Da-Silva AM, Laing GD, Wu Y, Richards A, Broadhead A,
et al. Antibody from mice immunized with DNA encoding the carboxyl-
disintegrin and cysteine-rich domain (JD9) of the haemorrhagic metal-
loprotease, Jararhagin, inhibits the main lethal component of viper venom.
Clin Exp Immunol 2000;121:358e63.
[124] Azofeifa-Cordero G, Arce-Estrada V, Flores-Díaz M, Alape-Girón A. Immuni-
zation with cDNA of a novel P-III type metalloproteinase from the rattle-
snake Crotalus durissus durissus elicits antibodies which neutralize 69% of the
hemorrhage induced by the whole venom. Toxicon 2008;52:302e8.
[125] Arce-Estrada V, Azofeifa-Cordero G, Estrada R, Alape-Girón A, Flores-Díaz M.
Neutralization of venom-induced hemorrhage by equine antibodies raised
by immunization with a plasmid encoding a novel P-II metalloproteinase
from the lancehead pitviper Bothrops asper. Vaccine 2009;27:460e6.
[126] Gopalakrishnakone P, Dempster DW, Hawgood BJ, Elder HY. Cellular and
mitochondrial changes induced in the structure of murine skeletal muscle
by crotoxin, a neurotoxic phospholipase A2 complex. Toxicon 1984;
22:85e98.
[127] Raw I, Rocha MC, Esteves MI, Kamiguti AS. Isolation and characterization of
a thrombin-like enzyme from the venom of Crotalus durissus terriﬁcus. Braz J
Med Biol Res 1986;19:333e8.
[128] Bon C. Multicomponent neurotoxic phospholipases A2. In: Kini RM, editor.
Venom phospholipase A2 enzymes: structure, function and mechanism.
Chichester: Wiley; 1997. p. 269e85.
[129] Olvera A, Ramos-Cerrillo B, Estevez J, Clement H, de Roodt A, Paniagua-
Solis J, et al. North and South American Loxosceles spiders: development of
a polyvalent antivenom with recombinant sphingomyelinases D as antigens.
Toxicon 2006;48:64e74.
[130] Nelson AL, Dhimolea E, Reichert JM. Development trends for human
monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9:767e74.
[131] Burnouf T. Recombinant plasma proteins. Vox Sang 2011;100:68e83.
[132] Tremeau O, Boulain JC, Couderc J, Fromageot P, Ménez A. A monoclonal
antibody which recognized the functional site of snake neurotoxins and
which neutralizes all short-chain variants. FEBS Lett 1986;208:236e40.
[133] Lomonte B, Kahan L. Production and partial characterization of monoclonal
antibodies to Bothrops asper (terciopelo) myotoxin. Toxicon 1988;
26:675e89.
[134] Choumet V, Faure G, Robbe-Vincent A, Saliou B, Mazie JC, Bon C. Immuno-
chemical analysis of a snake venom phospholipase A2 neurotoxin, crotoxin,
with monoclonal antibodies. Mol Immunol 1992;29:871e82.
[135] Estevao-Costa MI, Martins MS, Sanchez EF, Diniz CR, Chavez-Olortegui C.
Neutralization of the hemorrhagic activity of Bothrops and Lachesis snake
venoms by a monoclonal antibody against mutalysin-II. Toxicon 2000;
38:139e44.
[136] Tanjoni I, Butera D, Spencer PJ, Takehara HA, Fernandes I, Moura-da-
Silva AM. Phylogenetic conservation of a snake venom metalloproteinase
epitope recognized by a monoclonal antibody that neutralizes hemorrhagic
activity. Toxicon 2003;42:809e16.
[137] Fernandes I, Assumpcao GG, Silveira CR, Faquim-Mauro EL, Tanjoni I,
Carmona AK, et al. Immunochemical and biological characterization of
monoclonal antibodies against BaP1, a metalloproteinase from Bothrops
asper snake venom. Toxicon 2010;56:1059e65.
[138] Ménez A. Snake venom immunology. In: Harvey AL, editor. Snake toxins.
New York: Pergamon Press; 1991. p. 35e90.
[139] Selisko B, Cosio G, García C, Becerril B, Possani LD, Horjales E. Bacterial
expression, puriﬁcation and functional characterization of a recombinant
chimeric Fab derived from murine mAb BCF2 that neutralizes the venom of
the scorpion Centruroides noxius hoffmann. Toxicon 2004;43:43e51.
[140] Cardoso DF, Yamaguchi IK, Moura-da-Silva AM. Produçao de soros anti-
toxinas e perspectivas de modernização por técnicas de Biologia Molecular.
In: Cardoso JLC, França FOS, Wen FH, Málaque CMS, Haddad V, editors.
Animais Peçonhentos no Brasil Biologia, Clínica e Terapêutica dos Acidentes.
Sao Paulo: Sarvier; 2003. p. 367e79.
[141] Calvete JJ, Juárez P, Sanz L. Snake venomics. Strategy and applications. J Mass
Spectrom 2007;42:1405e14.
[142] Serrano SM, Shannon JD, Wang D, Camargo AC, Fox JW. A multifaceted
analysis of viperid snake venoms by two-dimensional gel electrophoresis: an
approach to understanding venom proteomics. Proteomics 2005;5:501e10.
[143] Meng J, John TR, Kaiser II. Speciﬁcity and binding afﬁnity of an anti-crotoxin
combinatorial antibody selected from a phage-displayed library. Biochem
Pharmacol 1995;50:1969e77.
[144] Lafaye P, Choumet V, Demangel C, Bon C, Mazie JC. Biologically active human
anti-crotoxin scFv isolated from a semi-synthetic phage library. Immuno-
technology 1997;3:117e25.[145] Tamarozzi MB, Soares SG, Marcussi S, Giglio JR, Barbosa JE. Expression of
recombinant human antibody fragments capable of inhibiting the phos-
pholipase and myotoxic activities of Bothrops jararacussu venom. Biochim
Biophys Acta 2006;1760:1450e7.
[146] Stewart CS, MacKenzie CR, Hall JC. Isolation, characterization and pen-
tamerization of alpha-cobrotoxin speciﬁc single-domain antibodies from
a naive phage display library: preliminary ﬁndings for antivenom develop-
ment. Toxicon 2007;49:699e709.
[147] Kulkeaw K, Sakolvaree Y, Srimanote P, Tongtawe P, Maneewatch S,
Sookrung N, et al. Human monoclonal ScFv neutralize lethal Thai cobra, Naja
kaouthia, neurotoxin. J Proteomics 2009;72:270e82.
[148] Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for
therapeutic applications. Curr Opin Investig Drugs 2009;10:1212e24.
[149] Hmila I, Abdallah RB, Saerens D, Benlasfar Z, Conrath K, Ayeb ME, et al. VHH,
bivalent domains and chimeric Heavy chain-only antibodies with high
neutralizing efﬁcacy for scorpion toxin AahI’. Mol Immunol 2008;
45:3847e56.
[150] Abderrazek RB, Hmila I, Vincke C, Benlasfar Z, Pellis M, Dabbek H, et al.
Identiﬁcation of potent nanobodies to neutralize the most poisonous poly-
peptide from scorpion venom. Biochem J 2009;424:263e72.
[151] Riaño-Umbarila L, Contreras-Ferrat G, Olamendi-Portugal T, Morelos-
Juarez C, Corzo G, Possani LD, et al. Exploiting cross-reactivity to neutralize
two different scorpion venoms with one single-chain antibody fragment. J
Biol Chem 2011;286:6143e51.
[152] Scherrmann JM. Antibody treatment of toxin poisoningerecent advances.
J Toxicol Clin Toxicol 1994;32:363e75.
[153] Gutiérrez JM, León G, Lomonte B. Pharmacokineticepharmacodynamic
relationships of immunoglobulin therapy for envenomation. Clin Pharma-
cokinet 2003;42:721e41.
[154] Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy
for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics
of immunoglobulin antivenoms and related antibodies. Ann Emerg Med
2001;37:189e95.
[155] Solano G, Segura A, Herrera M, Gómez A, Villalta M, Gutiérrez JM, et al. Study
of the design and analytical properties of the lethality neutralization assay
used to estimate antivenom potency against Bothrops asper snake venom.
Biologicals 2010;38:577e85.
[156] Sells PG. Animal experimentation in snake venom research and in vitro
alternatives. Toxicon 2003;42:115e33.
[157] Gutiérrez JM, Rucavado A, Escalante T, Lomonte B, Angulo Y, Fox JW. Tissue
pathology induced by snake venoms: how to understand a complex pattern
of alterations from a systems biology perspective? Toxicon 2010;55:166e70.
[158] Theakston RD, Reid HA. Enzyme-linked immunosorbent assay (ELISA) in
assessing antivenom potency. Toxicon 1979;17:511e5.
[159] Maria WS, Pacheco BG, Barbosa CF, Velarde DT, Chavez-Olortegui C. Deter-
mination of the neutralizing potency of horse antibothropic and anticrotalic
antivenoms in blood samples collected on ﬁlter paper. Toxicon 2001;
39:1607e9.
[160] Rial A, Morais V, Rossi S, Massaldi H. A new ELISA for determination of
potency in snake antivenoms. Toxicon 2006;48:462e6.
[161] Angulo Y, Estrada R, Gutiérrez JM. Clinical and laboratory alterations in
horses during immunization with snake venoms for the production of
polyvalent (Crotalinae) antivenom. Toxicon 1997;35:81e90.
[162] Alape-Girón A, Miranda-Arrieta K, Cortés-Bratti X, Stiles BG, Gutiérrez JM.
A comparison of in vitro methods for assessing the potency of therapeutic
antisera against the venom of the coral snake Micrurus nigrocinctus. Toxicon
1997;35:573e81.
[163] Gutiérrez JM, Avila C, Rojas E, Cerdas L. An alternative in vitro method for
testing the potency of the polyvalent antivenom produced in Costa Rica.
Toxicon 1988;26:411e3.
[164] Barfaraz A, Harvey AL. The use of the chick biventer cervicis preparation to
assess the protective activity of six international reference antivenoms on the
neuromuscular effects of snake venoms in vitro. Toxicon 1994;32:267e72.
[165] Fry BG, Wickramaratna JC, Jones A, Alewood PF, Hodgson WC. Species and
regional variations in the effectiveness of antivenom against the in vitro
neurotoxicity of death adder (Acanthophis) venoms. Toxicol Appl Pharmacol
2001;175:140e8.
[166] Lomonte B, Tarkowski A, Hanson LÅ. Broad cytolytic speciﬁcity of myotoxin
II, a lysine-49 p.ospholipase A2 of Bothrops asper snake venom. Toxicon
1994;32:1359e69.
[167] Kalam Y, Isbister GK, Mirtschin P, Hodgson WC, Konstantakopoulos N.
Validation of a cell-based assay to differentiate between the cytotoxic effects
of elapid snake venoms. J Pharmacol Toxicol Methods 2011;63:137e42.
[168] Sells PG, Ioannou P, Theakston RD. A humane alternative to the measure-
ment of the lethal effects (LD50) of non-neurotoxic venoms using hens’ eggs.
Toxicon 1998;36:985e91.
[169] Sells PG, Laing GD, Theakston RD. An in vivo but insensate model for the
evaluation of antivenoms (ED50) using fertile hens’ eggs. Toxicon 2001;
39:665e8.
[170] Hedge RP, Rajagopalan N, Doley R, Kini RM. Snake venom three-ﬁnger
toxins. In: Mackessy SP, editor. Venoms and toxins of reptiles. Boca Raton:
CRC Press; 2009. p. 287e301.
[171] Wagstaff SC, Sanz L, Juárez P, Harrison RA, Calvete JJ. Combined snake ven-
omics and venom gland transcriptomic analysis of the ocellated carpet viper,
Echis ocellatus. J Proteomics 2009;71:609e23.
J.M. Gutiérrez et al. / Biologicals 39 (2011) 129e142142[172] Terra RM, Pinto AF, Guimaraes JA, Fox JW. Proteomic proﬁling of snake
venom metalloproteinases (SVMPs): insights into venom induced pathology.
Toxicon 2009;54:836e44.
[173] Gutiérrez JM,EscalanteT,RucavadoA.Experimentalpathophysiologyofsystemic
alterations induced by Bothrops asper snake venom. Toxicon 2009;54:976e87.[174] Wagner C. The New Invisible College. Science for development. Washington,
D.C: Brooklings Institution Press; 2008.
[175] Williams D, Gutiérrez JM, Harrison R, Warrell DA, White J, Winkel KD, et al.
The global snake bite initiative: an antidote for snake bite. Lancet
2010;375:89e91.
